Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients

被引：0
|
作者：
Brueckner, A. J. [1 ]
Doligalski, C. T. [1 ]
Logan, A. T. [1 ]
机构：
[1] Tampa Gen Hosp, Pharm, Tampa, FL 33606 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2017年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1122
引用
收藏
页码：S365 / S366
页数：2
相关论文
共 50 条
  • [41] Epidemiology of CMV Disease in CMV-Naive Lung Transplant Recipients in the Era of Valganciclovir Prophylaxis.
    Mitsani, D.
    Vadnerkar, A.
    Silveira, F.
    Celik, U.
    Pilewski, J.
    Crespo, M.
    Nguyen, M. H.
    Clancy, C. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 291 - 291
  • [42] Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
    El Hajj, S.
    Azzi, J.
    Kim, M.
    Gabardi, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 948 - 948
  • [43] CMV IgG Provides Similar Anti-CMV Efficacy as Valganciclovir in High-Risk Organ Transplant Recipients, With Reduced Costs
    Pilch, N.
    Taber, D.
    Schaffner, C.
    Nadig, S.
    McGillicuddy, J.
    Bratton, C.
    Baliga, P.
    Chavin, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [44] Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: A systematic review and meta-analysis
    Kalil, Andre C.
    Mindru, Cezarina
    Botha, Jean F.
    Grant, Wendy J.
    Mercer, David F.
    Olivera, Marco A.
    McCartan, Megan A.
    McCashland, Timothy M.
    Langnas, Alan N.
    Florescu, Diana F.
    LIVER TRANSPLANTATION, 2012, 18 (12) : 1440 - 1447
  • [45] Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
    Johansson, Inger
    Martensson, Gunnar
    Nystrom, Ulla
    Nasic, Salmir
    Andersson, Rune
    BMC INFECTIOUS DISEASES, 2013, 13
  • [46] A prospective trial of valganciclovir prophylaxis for cytomegalovirus (CMV) prevention in lung transplant recipients.
    Humar, A
    Kumar, D
    Preiksaitis, J
    Fenton, J
    Nia, S
    Jackson, K
    Chernenko, S
    Lien, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 270 - 270
  • [47] Impact of Prolonging CMV Prophylaxis in High-Risk (CMV D plus /R-) Lung Transplant Recipients
    Herrera, S.
    Khan, B.
    Husain, S.
    Binnie, M.
    Chow, C.
    Martinu, T.
    Chaparro, C.
    Keshavjee, S.
    Singer, L. G.
    Tikkanen, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S120 - S120
  • [48] Preemptive vs. Upfront CMV Prophylaxis Strategies and the Risk of Treated CMV in Intermediate Risk Heart Transplant Recipients
    Chen, C.
    Eng, N.
    Aldridge, M.
    Itchell, H. M.
    Osborne, A.
    Morris, A.
    Hurtik, M.
    Gupta, D.
    Bhatt, K.
    Laskar, S.
    Vega, J.
    Smith, A.
    Cole, R. T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S355 - S355
  • [49] CMV PROPHYLAXIS WITH FOSCARNET IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS AT HIGH-RISK OF DEVELOPING CMV INFECTIONS
    BACIGALUPO, A
    TEDONE, E
    VANLINT, MT
    TRESPI, G
    LONNGREN, M
    SANNA, MA
    MORO, F
    FRASSONI, F
    OCCHINI, D
    GUALANDI, F
    LAMPARELLI, T
    FIGARI, O
    BENVENUTO, F
    RAFFO, MR
    SOGNO, G
    ISAZA, A
    DINEGRO, GB
    FELLETTI, R
    HALE, G
    MARMONT, AM
    BONE MARROW TRANSPLANTATION, 1994, 13 (06) : 783 - 788
  • [50] Rates of CMV Infection in Kidney Transplant Recipients Who Received Subtherapeutic Valganciclovir Prophylaxis
    Belfield, K.
    Cohen, E.
    Malinis, M.
    Baghban, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 514 - 514
12345